CD44 and posterior cortical atrophy: This study (Liu et al., 2011) demonstrated that miR-34a acts as a crucial negative regulator of (CD44+/hi) PCSCs and establishes a strong rationale for developing miR-34a as a novel therapeutic against aggressive and metastatic PCa (Liu et al., 2011).